Study study type PathologyT1T0Patientssample sizesROB Results

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus placebo plus SoC
atezolizumab plus SoC
IMpower-133, 2018
  NCT02763579
RCTExtensive stage SCLC (Es-SCLC) - 1st Line (L1)atezolizumab (as induction and maintenance therapy) plus carboplatin and etoposideplacebo plus carboplatin and etoposidepatients with extensive-Stage Small-Cell Lung Cancer who had not received previous systemic treatment201 / 202low
conclusif
  • demonstrated 30 % decrease in deaths (OS) (PE)
  • demonstrated 23 % decrease in progression or deaths (PFS) (PE)
  • suggested 24 % decrease in deaths (OS) (extension)
  • suggested 23 % decrease in PFS (extension)